| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 04/07/2022 | 04:47 | TipRanks | SVB Securities Sticks to Its Buy Rating for AbCellera Biologics (ABCL) | NASDAQ:ABCL | AbCellera Biologics Inc |
| 30/06/2022 | 19:28 | Edgar (US Regulatory) | Current Report Filing (8-k) | NASDAQ:ABCL | AbCellera Biologics Inc |
| 29/06/2022 | 17:04 | Business Wire | Lilly to Supply an Additional 150,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatment Options | NASDAQ:ABCL | AbCellera Biologics Inc |
| 08/06/2022 | 21:33 | Edgar (US Regulatory) | Statement of Changes in Beneficial Ownership (4) | NASDAQ:ABCL | AbCellera Biologics Inc |
| 11/05/2022 | 14:49 | TipRanks | AbCellera Biologics (ABCL) Receives a Buy from SVB Securities | NASDAQ:ABCL | AbCellera Biologics Inc |
| 11/05/2022 | 14:49 | TipRanks | BMO Capital Thinks AbCellera Biologics’ Stock is Going to Recover | NASDAQ:ABCL | AbCellera Biologics Inc |
| 11/05/2022 | 12:30 | TipRanks | Berenberg Bank Thinks AbCellera Biologics’ Stock is Going to Recover | NASDAQ:ABCL | AbCellera Biologics Inc |
| 10/05/2022 | 22:34 | Edgar (US Regulatory) | Quarterly Report (10-q) | NASDAQ:ABCL | AbCellera Biologics Inc |
| 10/05/2022 | 22:05 | Business Wire | AbCellera Reports Q1 2022 Business Results | NASDAQ:ABCL | AbCellera Biologics Inc |
| 03/05/2022 | 15:00 | Business Wire | AbCellera and Empirico Expand Strategic Multi-Target Antibody Discovery Collaboration | NASDAQ:ABCL | AbCellera Biologics Inc |
| 28/04/2022 | 20:36 | Edgar (US Regulatory) | Additional Proxy Soliciting Materials (definitive) (defa14a) | NASDAQ:ABCL | AbCellera Biologics Inc |
| 28/04/2022 | 20:34 | Edgar (US Regulatory) | Proxy Statement (definitive) (def 14a) | NASDAQ:ABCL | AbCellera Biologics Inc |
| 26/04/2022 | 22:05 | Business Wire | AbCellera to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference on May 2, 2022 | NASDAQ:ABCL | AbCellera Biologics Inc |
| 12/04/2022 | 22:05 | Business Wire | AbCellera to Report First Quarter 2022 Financial Results on May 10, 2022 | NASDAQ:ABCL | AbCellera Biologics Inc |
| 08/04/2022 | 19:05 | Business Wire | AbCellera Presents Data on T Cell Engager Platform at AACR 2022 | NASDAQ:ABCL | AbCellera Biologics Inc |
| 25/02/2022 | 21:55 | Edgar (US Regulatory) | Post-effective Amendment to Registration Statement (pos Am) | NASDAQ:ABCL | AbCellera Biologics Inc |
| 25/02/2022 | 21:51 | Edgar (US Regulatory) | Securities Registration: Employee Benefit Plan (s-8) | NASDAQ:ABCL | AbCellera Biologics Inc |
| 25/02/2022 | 20:16 | Edgar (US Regulatory) | Annual Report (10-k) | NASDAQ:ABCL | AbCellera Biologics Inc |
| 24/02/2022 | 22:05 | Business Wire | AbCellera Reports Full Year 2021 Business Results | NASDAQ:ABCL | AbCellera Biologics Inc |
| 23/02/2022 | 22:05 | Business Wire | AbCellera to Participate Virtually in the Truist Securities AI Symposium – Biotech & Tools | NASDAQ:ABCL | AbCellera Biologics Inc |
| 16/02/2022 | 12:00 | Edgar (US Regulatory) | Prospectus Filed Pursuant to Rule 424(b)(3) (424b3) | NASDAQ:ABCL | AbCellera Biologics Inc |
| 15/02/2022 | 00:34 | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) | NASDAQ:ABCL | AbCellera Biologics Inc |
| 12/02/2022 | 00:58 | Business Wire | AbCellera-Discovered Antibody, Bebtelovimab, Receives U.S. FDA Emergency Use Authorization for the Treatment of Mild-to-Moderate COVID-19 | NASDAQ:ABCL | AbCellera Biologics Inc |
| 11/02/2022 | 22:59 | Dow Jones News | Lilly Antibody Bebtelovimab Gets FDA EUA for Certain Mild-to-Moderate Covid-19 Patients | NASDAQ:ABCL | AbCellera Biologics Inc |
| 11/02/2022 | 22:05 | Business Wire | AbCellera to Present Virtually at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022 | NASDAQ:ABCL | AbCellera Biologics Inc |
| 11/02/2022 | 20:49 | Edgar (US Regulatory) | Schedule 13g | NASDAQ:ABCL | AbCellera Biologics Inc |
| 11/02/2022 | 01:40 | Business Wire | Lilly to Supply up to 600,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatments | NASDAQ:ABCL | AbCellera Biologics Inc |
| 04/02/2022 | 00:55 | Edgar (US Regulatory) | Annual Statement of Changes in Beneficial Ownership (5) | NASDAQ:ABCL | AbCellera Biologics Inc |
| 27/01/2022 | 22:05 | Business Wire | AbCellera to Report Full Year 2021 Financial Results on February 24, 2022 | NASDAQ:ABCL | AbCellera Biologics Inc |
| 21/12/2021 | 13:47 | TipRanks | Bloom Burton Initiates a Buy Rating on AbCellera Biologics (ABCL) | NASDAQ:ABCL | AbCellera Biologics Inc |